MindWalk Holdings (HYFT) Common Equity (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Common Equity of $8.6 million for Q2 2026, down 48.38% year-over-year from $16.6 million in Q2 2025, and down 19.95% quarter-over-quarter from $10.7 million in Q1 2026.
MindWalk Holdings (HYFT) Common Equity (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Common Equity for 7 consecutive years, with $8.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity fell 48.38% year-over-year to $8.6 million; the TTM figure through Apr 2026 stood at $8.6 million (down 48.38% YoY), while the FY2026 annual figure was $8.6 million, down 49.47% from the prior year.
- Common Equity eased to $8.6 million in Q2 2026 per HYFT's latest filing, from $10.7 million in the prior quarter.
- Across five years, Common Equity topped out at $59.4 million in Q2 2022 and bottomed at $8.6 million in Q2 2026.
- Historically, Common Equity has averaged $30.9 million across 5 years, with a median of $32.0 million in 2022.
- On a YoY basis, Common Equity climbed as much as 31.47% in 2022 and fell as far as 99.72% in 2022.
- MindWalk Holdings' Common Equity stood at $46.5 million in 2022, then declined by 15.76% to $39.2 million in 2023, then plunged by 40.36% to $23.4 million in 2024, then plunged by 45.35% to $12.8 million in 2025, then sank by 32.85% to $8.6 million in 2026.
- Business Quant data shows HYFT's Common Equity at $8.6 million in Q2 2026, $10.7 million in Q1 2026, and $12.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 8.57 Mn |
| Jan 31, 2026 | 10.71 Mn |
| Oct 31, 2025 | 12.76 Mn |
| Jul 31, 2025 | 15.10 Mn |
| Apr 30, 2025 | 16.60 Mn |
| Jan 31, 2025 | 17.58 Mn |
| Oct 31, 2024 | 23.35 Mn |
| Jul 31, 2024 | 23.98 Mn |
| Apr 30, 2024 | 26.31 Mn |
| Jan 31, 2024 | 37.82 Mn |
| Oct 31, 2023 | 39.16 Mn |
| Jul 31, 2023 | 41.02 Mn |
| Apr 30, 2023 | 43.24 Mn |
| Jan 31, 2023 | 45.29 Mn |
| Oct 31, 2022 | 46.49 Mn |
| Jul 31, 2022 | 51.50 Mn |
| Apr 30, 2022 | 59.44 Mn |
| Jan 31, 2022 | 37.68 Mn |
| Oct 31, 2021 | 40.49 Mn |
| Jul 31, 2021 | 45.13 Mn |